Two pathways, one clinical decision

Three things determine whether hip cartilage repair or hip replacement is the right next step: patient age, the size and depth of the cartilage damage, and how far osteoarthritis has progressed. Understanding where a patient sits on each axis makes the decision considerably clearer.

These are not equivalent alternatives available at any moment. Cartilage repair preserves the native joint and its biology; replacement substitutes a prosthesis when that biology can no longer support repair. They sit at different stages of the same clinical journey, not as rival options of equal suitability at any given point.

Moving too quickly in either direction carries a cost. For a younger patient who undergoes total hip replacement prematurely, a prosthetic hip has a finite lifespan — and a complex revision operation becomes increasingly likely across the following decades. For a patient whose osteoarthritis is already advanced, pursuing preservation instead closes off the appropriate intervention and adds months of unnecessary suffering without changing the eventual outcome.

A 42-year-old with a 2 cm² focal defect and an otherwise structurally sound hip sits firmly in preservation territory — provided the joint mechanics are right. Raise the osteoarthritis stage by one or two radiological grades, or extend the damage across multiple joint surfaces, and the calculus shifts toward replacement.

Alongside age, defect grade, and OA stage, a fourth question shapes every case: whether the underlying mechanical cause — femoroacetabular impingement, acetabular dysplasia, or a labral tear — has been identified and can be corrected. Repairing cartilage without addressing the force that damaged it shortens any repair's useful life.

How arthritis stage sets the starting point

The space inside the hip joint, visible on a plain X-ray, gives a surgeon their first structural answer. When that joint space is well preserved — Tönnis grade 0 or 1, meaning minimal or no narrowing — the hip's cartilage still has enough integrity to make preservation surgery worthwhile. For younger patients with focal defects at this stage, repair is the appropriate default.

The pivot comes at Tönnis grade 2, when joint-space narrowing becomes established across a meaningful portion of the joint. At this point, preservation procedures perform significantly less well: the tissue environment that makes cartilage repair viable is already compromised. The clinical conversation appropriately shifts toward arthritis management and, in time, replacement.

The Kellgren-Lawrence scale offers a parallel and better-known grading framework. A 2021 systematic review by Günther and colleagues (PMC8820083) established that total hip replacement is evidence-based only at Kellgren-Lawrence grade 3 or 4 — radiologically confirmed advanced arthritis — and only after at least three months of conservative treatment have failed to control symptoms adequately.

The genuinely difficult territory sits between these two thresholds: a Tönnis grade 1–2 or Kellgren-Lawrence grade 2–3 hip that is neither clearly preservation nor clearly replacement territory. No definitive protocol exists for this grey zone; shared decision-making between patient and clinician is required, weighing symptom burden and functional limitation alongside the X-ray picture.

Radiological grade is the starting point, not the whole answer. A patient with moderate X-ray changes but severe pain and functional loss may reach the replacement threshold sooner than the images alone suggest.

Age and defect size in the preservation window

For patients under roughly 45–50 with a focal defect in a Tönnis grade 0–1 hip, the question shifts from whether to preserve to how — and the evidence contains at least one result that surprises many patients.

Small defects of approximately 1 cm² or less (roughly the area of a fingernail) do not reliably benefit from microfracture when the underlying mechanical problem — typically femoroacetabular impingement — is corrected simultaneously. A 2022 multicentre study by Riedl and colleagues (n=40, ICRS grade ≥2) found that patients who received FAI correction alone showed significant iHOT-33 functional improvement at 12, 24, and 36 months; the group that also underwent microfracture did not. Preserving the subchondral bone plate intact while removing the impingement appears to give the joint the best chance of natural remodelling without additional cartilage intervention.

For medium defects in the 2–4 cm² range, single-stage procedures become appropriate. AMIC — matrix-augmented microfracture, in which a collagen scaffold stabilises repair tissue within a single operation — and osteochondral autograft transfer are both reasonable choices at this size. A 4-year controlled study in 112 hip arthroscopy patients (ICRS grade 2–4, defects ≤3 cm²) found that mesenchymal stem cell augmentation produced sustained functional improvement, while around 20% of the microfracture-only group showed late score deterioration — consistent with the recognised tendency of unsupported fibrocartilage to break down after a few years and the reason microfracture is no longer considered adequate as a standalone technique for most medium or larger defects.

For defects at or above roughly 2–3 cm², autologous chondrocyte transplantation (ACT or its membrane-based form, MACI) becomes the recommended step-up. The SUMMIT trial demonstrated superior outcomes for MACI over microfracture at both 2 and 5 years in defects of 3 cm² or more.

Whichever technique is selected, labral repair belongs in the same operation rather than a separate decision. Restoring the labrum's fluid-seal and the capsule's mechanical stability has been shown in preclinical work to significantly improve the quality of cartilage fill after microfracture. Hip architecture and hip cartilage repair cannot be treated in isolation.

Conservative care and injections before any surgical decision

Before either surgical pathway is finalised, structured conservative management serves as both a clinical prerequisite and a diagnostically useful stage. The minimum three-month threshold — noted earlier in the context of THR indications — applies equally to cartilage repair candidates: this period generates evidence that pain is genuinely joint-sourced, quantifies functional limitation, and gives hip-strengthening physiotherapy and any weight optimisation time to take effect. Where surgery does follow, both hip musculature condition and body weight independently influence outcomes.

Intra-articular injections contribute meaningfully during this phase. Corticosteroid injections can dampen acute inflammatory pain; hyaluronic acid (viscosupplementation) may reduce symptom burden in mild-to-moderate hip osteoarthritis. Biologic options — platelet-rich plasma (PRP) and bone-marrow aspirate concentrate (BMAC) — can extend the window before repair surgery is needed in appropriate candidates, though both function as adjuncts to eventual cartilage restoration rather than alternatives to it.

For patients with suitable focal defects who prefer to defer arthroscopic or open procedures, an injectable collagen scaffold treatment offers a further minimally invasive option. A ChondroFiller injection is delivered as an ultrasound-guided outpatient procedure and acts through matrix-induced chondrogenesis — recruiting the patient's own progenitor cells into the defect site. Published hip series report mHHS improvements in the region of 30 points. Unlike biologic injections, this is a scaffold-based regenerative pathway rather than a pain-management strategy: it sits in the restorative part of the bridge stage for patients with a focal defect not yet large enough to warrant a two-stage cell-based procedure.

The grey zone: patients in their 40s and 50s

Patients in their late 40s and early 50s occupy the most genuinely uncertain territory in this decision. Neither the preservation criteria — focal defect, Tönnis grade 0–1, correctable mechanical cause — nor the replacement threshold of KL grade 3–4 applies cleanly. That uncertainty is real rather than a framing convenience, and honest acknowledgement of it is more useful to most patients than a checklist answer.

The conversion data give the age-related risk a concrete shape. Among 53,103 hip arthroscopy patients, THA conversion within two years was 3.9% overall — but 28% for those aged 50–59 and 36% for those aged 60–69, against below 5% in patients under 40. Age materially modifies what joint-preserving surgery can reliably deliver.

Where a correctable mechanical cause exists — acetabular dysplasia being the clearest example — preservation may remain appropriate even at this age. Periacetabular osteotomy in patients aged 18–40 produced comparable ten-year outcomes to THR (mHHS 86.1 vs 82.6, revision rates approximately 8% in both groups), showing that addressing underlying mechanics can yield durable results without early arthroplasty.

For this borderline group, there is no definitive evidence-based protocol — a genuine clinical gap rather than an oversight. Three questions tend to frame shared decision-making: how symptomatic is the patient now; has OA progressed on serial imaging over the past year or two; and is there a correctable mechanical cause? For those who do proceed with joint-preserving repair, outcomes are tracked using the MERCH score — a seven-domain MRI framework (range −20 to +60) covering fill, integration, surface, structure, and subchondral changes — with expert consensus that reliable MRI evaluation is not possible before 12 months post-operatively. Lincolnshire Hip accepts patients without referral for the kind of specialist assessment this group needs most.

When total hip replacement becomes the right answer

Reaching the threshold for hip replacement is not a failure of the preservation strategy — it is the correct clinical destination once osteoarthritis has advanced past what cartilage repair can realistically address. The evidence-based indication is specific: Kellgren-Lawrence grade 3 or 4 OA, high subjective distress from the hip joint, and at least three months of documented conservative management that has not provided adequate relief. These criteria together constitute a positive indication for total hip arthroplasty, not a decision by default.

Implant longevity frames the timing argument in concrete terms. Approximately 90% of hip replacements remain functional at 15 years; that figure falls to around 58% at 25 years. For a patient in their mid-40s, the arithmetic almost guarantees a revision operation — a more complex, higher-risk procedure than the primary replacement — somewhere in their lifetime. That is the mechanical case for exhausting preservation options first, not sentiment.

For patients who have crossed that threshold, or who are genuinely uncertain whether they have, Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment. The service operates as a hip-replacement end-pathway offering, with surgery at Weymouth Street Hospital and post-operative physiotherapy available locally in Grantham and Sleaford for patients returning to Lincolnshire.

The journey from early cartilage damage to total hip replacement is rarely abrupt. Each stage described in this article — joint-space assessment, preservation-or-replacement thresholds, the grey zone of the late 40s and 50s — exists to help patients and their clinicians identify where they sit in that sequence, and to make a well-timed decision rather than either an overhasty or a delayed one.

1. [1] Hip Arthroscopy Volume and Reoperations: High Rate of Revision Arthroscopy in Young and THA Conversion in Older Patients. (2021). https://doi.org/10.1016/j.arthro.2021.04.017 https://doi.org/10.1016/j.arthro.2021.04.017
2. [2] Comparison of Modern Periacetabular Osteotomy for Hip Dysplasia with THA — 10-Year Outcomes Comparable in Young Adults. (2022). https://doi.org/10.1093/jhps/hnac029 https://doi.org/10.1093/jhps/hnac029
3. [3] Hip Articular Cartilage Repair with Autologous Mesenchymal Stem Cells (MSCs): 4-Year Results in Prospective Controlled Study. (2025). https://doi.org/10.1093/jhps/hnaf011.025 https://doi.org/10.1093/jhps/hnaf011.025
4. [4] Defining Hip Cartilage Repair: the Magnetic Resonance Evaluation of the Repair of Cartilage in the Hip (MERCH) Score. (2023). https://doi.org/10.1186/s40634-023-00676-y https://doi.org/10.1186/s40634-023-00676-y
5. [5] Trends in Cartilage Repair Techniques for Chondral Defects in the Hip in Germany: An Epidemiological Analysis 2006–2022. (2024). https://doi.org/10.3390/life14101262 https://doi.org/10.3390/life14101262
6. [6] Preserving Hip Stability Yields Better Cartilage Repair with Microfracture Treatment: A Rabbit Study. (2025). https://doi.org/10.1016/j.asmr.2025.101284 https://doi.org/10.1016/j.asmr.2025.101284